In a patient with a recent non‑ST‑segment elevation myocardial infarction (NSTEMI) and a basal ganglia intracerebral hemorrhage, when is it appropriate to restart antiplatelet therapy?

Restarting Antiplatelet Therapy After NSTEMI with Basal Ganglia Bleed

In a patient with recent NSTEMI and basal ganglia intracerebral hemorrhage (ICH), resuming antiplatelet therapy beyond 24 hours after ICH symptom onset is reasonable when there is a strong indication for secondary prevention of major adverse cardiovascular events (MACE), with aspirin monotherapy being the preferred initial approach within a few days of ICH onset.

Evidence-Based Timing and Decision Framework

Timing of Reinitiation

The 2023 international guidelines provide convergent recommendations on timing 1:

• UK/Ireland guideline: Antiplatelet treatment may be restarted beyond 24 hours after ICH symptom onset
• Chinese guideline: Aspirin monotherapy can be restored within a few days from ICH onset, though optimal timing remains uncertain
• Canadian/US guidelines: Resumption is reasonable based on individualized benefit-risk assessment

Research evidence supports early resumption. A 2023 retrospective study of 1,584 ICH survivors found that early antiplatelet resumption (≤30 days) was as safe as delayed resumption (31-365 days), with similar 1-year recurrent ICH rates (3.12% vs 3.27%; adjusted HR 0.967) 2. Notably, early resumption showed lower mortality in patients without prior cerebrovascular disease.

Clinical Decision Algorithm

Your patient has ICH associated with antithrombotic use AND a history of MACE (the recent NSTEMI):

1. Strong indication exists to START antiplatelet therapy given the recent NSTEMI 1
2. Timing: Consider restarting after 24-48 hours if neuroimaging shows stability
3. Agent selection: Use aspirin monotherapy initially (not dual antiplatelet therapy)
4. Monitoring: Serial neuroimaging to confirm ICH stability before escalation

Critical Considerations for Your NSTEMI Patient

The recent coronary stent creates additional complexity:

• The 2025 ACC/AHA ACS guidelines recommend dual antiplatelet therapy (DAPT) for at least 12 months post-PCI as the default strategy 3
• However, ICH represents a high bleeding risk scenario that fundamentally alters this recommendation
• A staged approach is warranted, as demonstrated in a 2026 case report where short-acting, reversible agents (cangrelor, then clopidogrel) were used with serial neuroimaging guidance 4

Recommended Staged Approach

Phase 1 (24-72 hours post-ICH):

• Restart aspirin monotherapy (81-100 mg daily) if neuroimaging stable
• Hold P2Y12 inhibitor initially

Phase 2 (3-7 days post-ICH):

• If repeat imaging confirms ICH stability, consider adding clopidogrel (not ticagrelor/prasugrel due to higher bleeding risk)
• Avoid prasugrel and ticagrelor given their more potent antiplatelet effects

Phase 3 (Beyond 1 month):

• If tolerated, continue DAPT for minimum 3-6 months (shortened from standard 12 months due to ICH)
• Consider transitioning to P2Y12 inhibitor monotherapy (clopidogrel) after 1-4 weeks per bleeding risk mitigation strategies 3

Key Evidence Nuances

The RESTART Trial Findings

The landmark RESTART trial (2019) counterintuitively showed antiplatelet agents did not increase recurrent ICH risk compared to avoidance (adjusted HR 0.51,95% CI 0.25-1.03) 1. This finding has been incorporated into all major 2023 guidelines, though evidence remains Level B due to:

• Small sample size (537 patients)
• UK-only population
• MACE as secondary outcome requiring confirmation

Basal Ganglia Location Considerations

While guidelines don't specifically address ICH location, basal ganglia hemorrhages typically result from hypertensive small vessel disease. The RESTART trial included predominantly deep ICH (similar to your patient), and antiplatelet resumption appeared safe in this population 1.

Critical Pitfalls to Avoid

1. Do not resume ticagrelor or prasugrel - Use clopidogrel if P2Y12 inhibitor needed, as it has lower bleeding risk
2. Do not delay beyond 7 days without strong contraindication - Research shows early resumption (≤30 days) is safe and may reduce mortality 2
3. Do not use full-intensity DAPT indefinitely - Plan for de-escalation to monotherapy by 1-4 weeks given bleeding history 3
4. Do not restart without repeat neuroimaging - Confirm ICH stability before any antiplatelet escalation 4

Balancing Competing Risks

Your patient faces dual high-risk scenarios:

• Thrombotic risk: Recent NSTEMI with stent = very high MACE risk without antiplatelet therapy
• Hemorrhagic risk: Recent basal ganglia ICH = elevated rebleeding risk with antiplatelet therapy

A 2022 retrospective study found that antiplatelet resumption actually reduced recurrent ICH risk (HR 0.180) while preventing ischemic events (HR 0.240) 5. This supports the safety of resumption in patients with strong cardiovascular indications like your NSTEMI patient.

The evidence strongly favors restarting antiplatelet therapy in your patient, given the recent NSTEMI represents a "strong indication" that outweighs rebleeding concerns when using a staged, monitored approach 1.